The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes-Reference-Cited by-同舟云学术

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Published:2020-09-15 Issue:12 Volume:22 Page:2451-2459
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Wilson Jonathan M.¹,Nikooienejad Amir¹,Robins Deborah A.¹^ORCID,Roell William C.¹,Riesmeyer Jeffrey S.¹,Haupt Axel¹^ORCID,Duffin Kevin L.¹,Taskinen Marja‐Riitta²,Ruotolo Giacomo¹^ORCID

Affiliation:

1. Eli Lilly and Company Indianapolis Indiana USA

2. Research Program for Clinical and Molecular Medicine Unit Diabetes and Obesity, University of Helsinki Helsinki Finland

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14174

Reference47 articles.